161 related articles for article (PubMed ID: 26819111)
1. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients.
Gebhardt C; Lichtenberger R; Utikal J
J Dtsch Dermatol Ges; 2016 Feb; 14(2):158-64. PubMed ID: 26819111
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
3. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.
Wieder HA; Tekin G; Rosenbaum-Krumme S; Klode J; Altenbernd J; Bockisch A; Nagarajah J
Nuklearmedizin; 2013; 52(5):198-203. PubMed ID: 23969722
[TBL] [Abstract][Full Text] [Related]
4. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
5. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
7. Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay.
Blokzijl A; Chen LE; Gustafsdottir SM; Vuu J; Ullenhag G; Kämpe O; Landegren U; Kamali-Moghaddam M; Hedstrand H
PLoS One; 2016; 11(4):e0154214. PubMed ID: 27110718
[TBL] [Abstract][Full Text] [Related]
8. Circulating melanoma exosomes as diagnostic and prognosis biomarkers.
Alegre E; Zubiri L; Perez-Gracia JL; González-Cao M; Soria L; Martín-Algarra S; González A
Clin Chim Acta; 2016 Feb; 454():28-32. PubMed ID: 26724367
[TBL] [Abstract][Full Text] [Related]
9. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma.
Peric B; Zagar I; Novakovic S; Zgajnar J; Hocevar M
BMC Cancer; 2011 Aug; 11():328. PubMed ID: 21810220
[TBL] [Abstract][Full Text] [Related]
10. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
[TBL] [Abstract][Full Text] [Related]
11. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
12. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
13. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Br J Dermatol; 1999 Jun; 140(6):1065-71. PubMed ID: 10354072
[TBL] [Abstract][Full Text] [Related]
15. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
16. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
Bouwhuis MG; Suciu S; Kruit W; Salès F; Stoitchkov K; Patel P; Cocquyt V; Thomas J; Liénard D; Eggermont AM; Ghanem G;
Eur J Cancer; 2011 Feb; 47(3):361-8. PubMed ID: 21087856
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma.
Wang TS; Johnson TM; Cascade PN; Redman BG; Sondak VK; Schwartz JL
J Am Acad Dermatol; 2004 Sep; 51(3):399-405. PubMed ID: 15337983
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
20. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients.
Damude S; Hoekstra HJ; Bastiaannet E; Muller Kobold AC; Kruijff S; Wevers KP
Eur J Surg Oncol; 2016 Apr; 42(4):545-51. PubMed ID: 26831006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
